Is KROS or ANNX more profitable?

Annexon has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Keros Therapeutics -256.60% -21.40% -19.79% Annexon N/A -106.15% -79.82%

Keros Therapeutics (KROS) Competitors

$11.19 -0.17 (-1.50%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$11.02 -0.17 (-1.53%)

As of 09/18/2026 07:57 PM Eastern

Compare

KROS vs. IMMX, RIGL, CLYM, DBVT, and ANNX

Should you buy Keros Therapeutics stock or one of its competitors? Keros Therapeutics's main competitors and comparable companies include Immix Biopharma (IMMX), Rigel Pharmaceuticals (RIGL), Climb Bio (CLYM), DBV Technologies (DBVT), and Annexon (ANNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Keros Therapeutics compare to Immix Biopharma?

Keros Therapeutics (NASDAQ:KROS) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

In the previous week, Immix Biopharma had 3 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Immix Biopharma and 0 mentions for Keros Therapeutics. Immix Biopharma's average media sentiment score of 1.03 beat Keros Therapeutics' score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Keros Therapeutics	Neutral
Immix Biopharma	Positive

Keros Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Keros Therapeutics has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Keros Therapeutics currently has a consensus price target of $20.50, suggesting a potential upside of 83.20%. Immix Biopharma has a consensus price target of $22.86, suggesting a potential upside of 82.86%. Given Keros Therapeutics' higher probable upside, research analysts plainly believe Keros Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Immix Biopharma has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
Immix Biopharma	N/A	-38.44%	-34.72%

Summary

Keros Therapeutics beats Immix Biopharma on 8 of the 15 factors compared between the two stocks.

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Rigel Pharmaceuticals has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.93	$367.02M	$16.32	2.86
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A

Rigel Pharmaceuticals has a net margin of 116.30% compared to Keros Therapeutics' net margin of -256.60%. Rigel Pharmaceuticals' return on equity of 22.95% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

In the previous week, Rigel Pharmaceuticals had 6 more articles in the media than Keros Therapeutics. MarketBeat recorded 6 mentions for Rigel Pharmaceuticals and 0 mentions for Keros Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.42 beat Keros Therapeutics' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Rigel Pharmaceuticals	Neutral
Keros Therapeutics	Neutral

Rigel Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

Rigel Pharmaceuticals presently has a consensus target price of $59.00, suggesting a potential upside of 26.50%. Keros Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 83.20%. Given Keros Therapeutics' higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats Keros Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Keros Therapeutics compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Climb Bio currently has a consensus target price of $26.92, suggesting a potential upside of 91.62%. Keros Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 83.20%. Given Climb Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Climb Bio is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Keros Therapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A

Climb Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

In the previous week, Climb Bio had 7 more articles in the media than Keros Therapeutics. MarketBeat recorded 7 mentions for Climb Bio and 0 mentions for Keros Therapeutics. Climb Bio's average media sentiment score of 0.68 beat Keros Therapeutics' score of 0.00 indicating that Climb Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Climb Bio	Positive
Keros Therapeutics	Neutral

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Climb Bio has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

Summary

Climb Bio and Keros Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

DBV Technologies has a beta of -0.95, suggesting that its stock price is 195% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Keros Therapeutics has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	137.69	-$146.95M	-$3.51	N/A
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A

In the previous week, DBV Technologies had 3 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for DBV Technologies and 0 mentions for Keros Therapeutics. DBV Technologies' average media sentiment score of 1.11 beat Keros Therapeutics' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
DBV Technologies	Positive
Keros Therapeutics	Neutral

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Keros Therapeutics has a net margin of -256.60% compared to DBV Technologies' net margin of -3,506.53%. Keros Therapeutics' return on equity of -21.40% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

DBV Technologies currently has a consensus target price of $48.50, suggesting a potential upside of 292.71%. Keros Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 83.20%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

DBV Technologies and Keros Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Annexon?

Keros Therapeutics (NASDAQ:KROS) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

71.6% of Keros Therapeutics shares are held by institutional investors. 12.6% of Keros Therapeutics shares are held by insiders. Comparatively, 10.3% of Annexon shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Keros Therapeutics currently has a consensus target price of $20.50, suggesting a potential upside of 83.20%. Annexon has a consensus target price of $15.14, suggesting a potential upside of 257.99%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Keros Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, Annexon has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

In the previous week, Annexon had 2 more articles in the media than Keros Therapeutics. MarketBeat recorded 2 mentions for Annexon and 0 mentions for Keros Therapeutics. Annexon's average media sentiment score of 0.49 beat Keros Therapeutics' score of 0.00 indicating that Annexon is being referred to more favorably in the news media.

Company	Overall Sentiment
Keros Therapeutics	Neutral
Annexon	Neutral

Keros Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.91	$87.01M	-$3.70	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

Annexon has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -21.40% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
Annexon	N/A	-106.15%	-79.82%

Summary

Annexon beats Keros Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KROS vs. The Competition

Export

Metric	Keros Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$221.86M	$3.89B	$7.24B	$13.21B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-3.02	14.23	275.49	25.40
Price / Sales	0.91	1,419.61	639.63	86.88
Price / Cash	2.47	108.90	76.25	51.42
Price / Book	0.72	15.45	10.46	6.33
Net Income	$87.01M	-$22.86M	$3.49B	$358.33M
7 Day Performance	0.99%	-1.21%	0.59%	1.12%
1 Month Performance	2.19%	-3.29%	-1.74%	-2.39%
1 Year Performance	-28.08%	37.74%	18.13%	5.35%

Keros Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KROS Keros Therapeutics	2.544 of 5 stars	$11.19 -1.5%	$20.50 +83.2%	-28.1%	$221.86M	$244.06M	N/A	92	Buyback Announcement
IMMX Immix Biopharma	3.5651 of 5 stars	$12.70 +3.2%	$21.29 +67.6%	+470.8%	$880.65M	N/A	N/A	9	Positive News Analyst Forecast Gap Up
RIGL Rigel Pharmaceuticals	4.5332 of 5 stars	$47.28 +0.1%	$59.00 +24.8%	+34.3%	$873.67M	$294.28M	2.90	160
CLYM Climb Bio	3.4962 of 5 stars	$14.95 -0.7%	$26.92 +80.1%	+508.2%	$864.42M	N/A	N/A	9	Analyst Upgrade Insider Trade
DBVT DBV Technologies	3.4883 of 5 stars	$12.97 -3.5%	$48.50 +273.9%	+30.0%	$845.04M	$5.64M	N/A	80	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KROS) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Competitors

KROS vs. IMMX, RIGL, CLYM, DBVT, and ANNX

How does Keros Therapeutics compare to Immix Biopharma?

Summary

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Summary

How does Keros Therapeutics compare to Climb Bio?

Summary

How does Keros Therapeutics compare to DBV Technologies?

Summary

How does Keros Therapeutics compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Competitors

KROS vs. IMMX, RIGL, CLYM, DBVT, and ANNX

How does Keros Therapeutics compare to Immix Biopharma?

Does the media favor KROS or IMMX?

Which has more risk and volatility, KROS or IMMX?

Which has preferable earnings and valuation, KROS or IMMX?

Do institutionals and insiders hold more shares of KROS or IMMX?

Do analysts prefer KROS or IMMX?

Is KROS or IMMX more profitable?

Summary

How does Keros Therapeutics compare to Rigel Pharmaceuticals?

Which has higher earnings and valuation, RIGL or KROS?

Is RIGL or KROS more profitable?

Does the media favor RIGL or KROS?

Which has more volatility and risk, RIGL or KROS?

Do analysts prefer RIGL or KROS?

Do institutionals and insiders hold more shares of RIGL or KROS?

Summary

How does Keros Therapeutics compare to Climb Bio?

Do analysts prefer CLYM or KROS?

Which has preferable valuation & earnings, CLYM or KROS?

Which has more risk & volatility, CLYM or KROS?

Does the media refer more to CLYM or KROS?

Do institutionals and insiders hold more shares of CLYM or KROS?

Is CLYM or KROS more profitable?

Summary

How does Keros Therapeutics compare to DBV Technologies?

Which has more risk and volatility, DBVT or KROS?

Which has better earnings & valuation, DBVT or KROS?

Does the media refer more to DBVT or KROS?

Do institutionals and insiders have more ownership in DBVT or KROS?

Is DBVT or KROS more profitable?

Do analysts rate DBVT or KROS?

Summary

How does Keros Therapeutics compare to Annexon?

Do insiders & institutionals hold more shares of KROS or ANNX?

Do analysts rate KROS or ANNX?

Which has more risk & volatility, KROS or ANNX?

Does the media refer more to KROS or ANNX?

Which has preferable valuation and earnings, KROS or ANNX?

Is KROS or ANNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools